Trading update for the second quarter
In regard to the acquisition of Igenomix and the subsequent directed share issue, Vitrolife is presenting sales and preliminary income for the second quarter.Second quarter · Sales amounted to SEK 382 (209) million, corresponding to an increase of 83 percent in SEK. Sales increased by 94 percent in local currency. · The preliminary operating income before depreciation and amortisation (EBITDA) amounted to SEK 134 (40) million, corresponding to a margin of 35 (19) percent. Fluctuations in exchange rates negatively impacted EBITDA by SEK 15 million. The operating income included non-